VISEN Pharmaceuticals (2561) Stock Statistics & Valuation Metrics

VISEN Pharmaceuticals has a market cap or net worth of HK$2.29B. The enterprise value is HK$1.70B.

VISEN Pharmaceuticals has 113,926,865 shares outstanding. The number of shares has decreased by -2.65% in one year.

VISEN Pharmaceuticals’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -24.87%.

The current PE Ratio of VISEN Pharmaceuticals is ―. VISEN Pharmaceuticals’s PEG ratio is -0.56.

In the last 12 months, VISEN Pharmaceuticals had revenue of 160.73K and earned -246.86M in profits. Earnings per share was -2.38.

In the last 12 months, operating cash flow was -180.24M and capital expenditures -117.00K, giving a free cash flow of -180.36M billion.

VISEN Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

VISEN Pharmaceuticals upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).

VISEN Pharmaceuticals as a current ratio of 4.47, with Debt / Equity ratio of 23.22%

In the past 12 months, VISEN Pharmaceuticals has paid 0.00 in taxes.

VISEN Pharmaceuticals EV to EBITDA ratio is -11.12, with an EV/FCF ratio of -5.77.

VISEN Pharmaceuticals has HK$805.91M in cash and marketable securities with HK$1.20M in debt, giving a net cash position of HK$804.71M billion.

Gross margin is 100.00%, with operating margin of -145329.04%, and net profit margin of -153589.68%.

The average price target for VISEN Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―